clinical trial · NCT07286032
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.·phase3·recruiting·n = 150
Patients With Chemotherapy-Induced ThrombocytopeniaHetrombopag OlamineHetrombopag Olamine ；Hetrombopag Olamine Placebo
brief summary
The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
started
Apr 16, 2026
primary completion
Dec 1, 2028
completion
Jun 1, 2029
last updated
Apr 30, 2026
official title
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol